"We expect the financials, very clean balance sheet, no debt for the company, 56.5 million shares outstanding as of the end of March, $104 million in the bank with another $12.5 million of anticipated milestone coming from Merck literally within the next few weeks."
le esta entrando pasta a ver lo q dura, no voy a poder seguir la sesión asin q suerte a toos
5,69 max dia ... ummmm ....
Respuesta de THLD acerca del trial que comentaba Framus, u que aparece con la leyende "unknow" en cliniclastrial, porqué hace más de 2 años que no actualizan el estado...
Dear Francesc,
The trial is still recruiting patients. Preliminary data were reported at a medical conference last fall (poster attached here).
Sincerely,
Laura Hansen
Laura G. Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals, Inc.
170 Harbor Way, Suite 300
South San Francisco, CA 94080
(650) 474-8206
Si señor, preguntando directamente a la fuente.
:)
Results
. 12 patients have been enrolled and underwent craniotomy, receiving placebo prior to surgery and 8 Patients Evaluable for Response N=Median Range
receiving TH-302.
• 8 patients went on to post-surgical treatment with bevacizumab and TH-302 under dose escalation.
• 2 patients withdrew consent after surgery, and 2 failed to recover sufficiently to meet ongoing eligibility
criteria.
• No DLTs occurred at 240mg/m2 or 340mg/m2 ; the third cohort at 480mg/m2 is ongoing.
• No grade 3 or 4 adverse events (AEs) were reported at 240 mg/m2; one grade 3 (skin ulceration) and no grade 4 AEs were reported at 340 mg/m2 to date. The primary TH-302 related toxicities were mucosal which have been managed conservatively.
• Extensive areas of hypoxia were observed by immunohistochemistry in surgical specimens and
there was a strong concordance between both exogenous (pimonidazole) and endogeous (CAIX)
markers of hypoxia (Figure 4 b) in serial sections.
• 6 patients were evaluable for response, with 1 unconfirmed partial response (Figure 5) and 4 demonstrating stable disease (Figure 6 and Table 1) .
• The longest disease stabilization is currently ongoing at 9.1 months and receiving cycle Figure 7).
Doce dias seguidos entrando sangre azul, I like it!
THLD
Señores,enhorabuena por su hilo,sin duda el mejor de rankia. Desde hace un mes les acompaño en esta empresa. Solo decir que a fecha de hoy supone el 68% de mi cartera. Buen valor, buen estado financiero, buen producto. Un saludo
